Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Q24201586)

metastatic endometrial carcinoma

inferred from title

1 reference

2

0 references

author name string

Claire L Vale

series ordinal

1

0 references

Sarah J Bull

series ordinal

3

0 references

Paul R Symonds

series ordinal

4

0 references

publication date

15 August 2012

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Cancer of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Revised FIGO staging for carcinoma of the endometrium

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Adjuvant chemotherapy for endometrial cancer after hysterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Hormonal therapy in advanced or recurrent endometrial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Reporting results of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Practical methods for incorporating summary time-to-event data into meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

Phase III randomized trial of doxorubicin cisplatin versus doxorubicin 24-h paclitaxel filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

21 January 2018

1 reference

12 December 2020

Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens

1 reference

12 December 2020

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

1 reference

12 December 2020

Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer

1 reference

12 December 2020

Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma

1 reference

12 December 2020

Treatment failure in endometrial carcinoma

1 reference

12 December 2020

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

1 reference

12 December 2020

Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group

1 reference

12 December 2020

Changes in the treatment of endometrial cancer

1 reference

12 December 2020

Global cancer statistics

1 reference

12 December 2020

Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration

1 reference

12 December 2020

Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group

1 reference

12 December 2020

Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study

1 reference

12 December 2020

Performance of the dipalmitoyl phosphatidylcholine test in predicting respiratory distress syndrome in contaminated samples of amniotic fluid.

1 reference

https://api.crossref.org/works/10.1002/14651858.CD003915.PUB4

7 January 2021